Explanipedia

Urine Cell Transcriptomes Implicate Specific Renal Inflammatory Pathways Associated With Difficult‐to‐Control Hypertension Open

Kausik Umanath, Ruicong She, Clare Hassett, Indra Adrianto, Albert M. Levin , et al. · 2023

Background The renal mechanisms involved in the maintenance of human hypertension and resistance to treatment are not well understood. Animal studies suggest that chronic renal inflammation contributes to hypertension. We studied cells she…

“Dip” in eGFR: Stay the Course With SGLT-2 Inhibition Open

Kausik Umanath, Jeffrey M. Testani, Julia B. Lewis · 2022

POS-255 EFFECT OF DAPAGLIFLOZIN ON BLOOD PRESSURE IN PATIENTS WITH CKD: A PRE-SPECIFIED ANALYSIS FROM DAPA-CKD Open

Michele Provenzano, Robert D. Toto, Priya Vart, Kausik Umanath, José Luis Górriz , et al. · 2022

Hypertension is common in patients with chronic kidney disease (CKD). Sodium-glucose cotransporter 2 inhibitors decrease blood pressure in patients with type 2 diabetes, but the consistency and magnitude of blood pressure lowering with dap…

Front Matter Open

Mustafa Ahmad, K. Sheraz Fahad, Jafar Alsaid, Carmichael Angeles, Kisra Anis , et al. · 2022

Pharmacological Effects of Ex Vivo Mesenchymal Stem Cell Immunotherapy in Patients with Acute Kidney Injury and Underlying Systemic Inflammation Open

Madhav Swaminathan, Nelson Kopyt, Mohamed G. Atta, Jai Radhakrishnan, Kausik Umanath , et al. · 2021

Mesenchymal stem cells (MSCs) have natural immunoregulatory functions that have been explored for medicinal use as a cell therapy with limited success. A phase Ib study was conducted to evaluate the safety and immunoregulatory mechanism of…

High SARS-CoV-2 Viral Load in Urine Sediment Correlates with Acute Kidney Injury and Poor COVID-19 Outcome Open

Paulo S. Caceres, Gina Savickas, Shannon L. Murray, Kausik Umanath, Junior Uduman , et al. · 2021

Significance statement AKI has been recognized as a common complication of coronavirus disease 2019 (COVID-19) and is associated with disease severity and mortality. The mechanisms behind these associations remain obscure, due, in part, to…

A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy Open

David C. Wheeler, Robert D. Toto, Bergur V. Stefánsson, Niels Jongs, Glenn M. Chertow , et al. · 2021

POS-832 DAPAGLIFLOZIN IN IgA NEPHROPATHY: FINDINGS FROM THE DAPA-CKD TRIAL Open

Hiddo J.L. Heerspink, Robert D. Toto, Niels Jongs, Priya Vart, Glenn M. Chertow , et al. · 2021

IgA nephropathy (IgAN) is the most common primary glomerulonephritis globally. Despite the use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers, up to 40% of patients with IgAN are at risk of progressing to end…

The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics Open

David C. Wheeler, Bergur V. Stefánsson, М. М. Батюшин, Oleksandr Bilchenko, David Z.I. Cherney , et al. · 2020

Background The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD; NCT03036150) trial was designed to assess the effect of the sodium–glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin on kidney and …

Hypertension: A Common but Complex Condition Open

Kausik Umanath · 2019

Correction to: Health care providers’ support of patients’ autonomy, phosphate medication adherence, race and gender in end-stage renal disease Open

Ebele M. Umeukeje, Joseph R. Merighi, Teri Browne, Marcus G. Wild, Hafez Alsmaan , et al. · 2019

Diabetic Kidney Disease: The Tiger May Have New Stripes Open

Kausik Umanath, Julia B. Lewis · 2018

Update on Diabetic Nephropathy: Core Curriculum 2018 Open

Kausik Umanath, Julia B. Lewis · 2018

Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT) Open

Michael V. Rocco, Kaycee M. Sink, Laura Lovato, Dawn F. Wolfgram, Thomas Wiegmann , et al. · 2017

Orthostatic changes in systolic blood pressure among SPRINT participants at baseline Open

Raymond R. Townsend, Tara I. Chang, Debbie L. Cohen, William C. Cushman, Gregory W. Evans , et al. · 2016

Health care providers’ support of patients’ autonomy, phosphate medication adherence, race and gender in end stage renal disease Open

Ebele M. Umeukeje, Joseph R. Merighi, Teri Browne, Marcus G. Wild, Hafez Alsmaan , et al. · 2016

Ferric Citrate, an Iron-Based Phosphate Binder, Reduces Health Care Costs in Patients on Dialysis Based on Randomized Clinical Trial Data Open

Roger A. Rodby, Kausik Umanath, Robert Niecestro, T. Christopher Bond, Mohammed Sika , et al. · 2015

The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial Open

Peter Van Buren, Julia B. Lewis, Jamie P. Dwyer, Tom Greene, John P. Middleton , et al. · 2015

FP590FERRIC CITRATE (FC) AS A PHOSPHATE BINDER IN PERITONEAL DIALYSIS (PD) Open

Negoi Dana, Jamie P. Dwyer, Julia B. Lewis, Kausik Umanath, Stephen Z. Fadem , et al. · 2015

SP657GASTROINTESTINAL SAFETY AND TOLERABILITY OF FERRIC CITRATE IN PATIENTS WITH ESRD ON DIALYSIS: A POOLED ANALYSIS Open

Gil Chernin, Ingrid J. Chang, Udayan Bhatt, Andrea Núñez Ortiz, Sean Barry , et al. · 2015

Self-Motivation Is Associated With Phosphorus Control in End-Stage Renal Disease Open

Ebele M. Umeukeje, Joseph R. Merighi, Teri Browne, Jacquelyn N. Victoroff, Kausik Umanath , et al. · 2015

Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD Open

Kausik Umanath, Diana Jalal, Barbara Greco, Ebele M. Umeukeje, Efrain Reisin , et al. · 2015

Ferric citrate (FC) is a phosphate binder with shown efficacy and additional effects on iron stores and use of intravenous (iv) iron and erythropoiesis-stimulating agents (ESAs). We provide detailed analyses of changes in iron/hematologic …

Kausik Umanath YOU? Author Swipe